Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$40.13
-0.2%
$41.84
$31.01
$50.21
$20.38B0.623.62 million shs2.01 million shs
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$231.55
+0.5%
$239.43
$229.40
$287.32
$66.89B0.431.37 million shs706,426 shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$73.17
-0.1%
$67.68
$48.35
$74.39
$107.35B0.786.59 million shs8.79 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$124.34
-9.9%
$130.98
$74.75
$142.00
$49.24B1.23.05 million shs8.55 million shs
3M stock logo
MMM
3M
$91.83
+0.5%
$95.70
$71.12
$95.67
$50.82B1.025.73 million shs4.50 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
-1.71%+1.48%-3.13%+3.71%-12.70%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-1.39%-1.15%-4.73%-2.58%-10.85%
Boston Scientific Co. stock logo
BSX
Boston Scientific
+0.53%+8.72%+7.89%+19.91%+43.44%
DexCom, Inc. stock logo
DXCM
DexCom
+0.10%+2.76%-1.37%+13.16%+10.47%
3M stock logo
MMM
3M
-0.65%-0.07%-10.92%-4.77%-11.17%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Baxter International Inc. stock logo
BAX
Baxter International
4.8162 of 5 stars
3.13.02.54.03.01.72.5
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.8984 of 5 stars
2.45.03.34.02.82.52.5
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.3914 of 5 stars
2.53.00.04.22.62.52.5
DexCom, Inc. stock logo
DXCM
DexCom
4.9573 of 5 stars
3.55.00.04.72.62.53.1
3M stock logo
MMM
3M
4.5518 of 5 stars
3.03.04.22.83.12.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
2.22
Hold$46.3015.38% Upside
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.80
Moderate Buy$280.0020.92% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
2.95
Moderate Buy$75.092.63% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.6713.93% Upside
3M stock logo
MMM
3M
2.00
Hold$104.0013.25% Upside

Current Analyst Ratings

Latest BSX, BDX, BAX, DXCM, and MMM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$70.00 ➝ $78.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$151.00 ➝ $160.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$144.00 ➝ $145.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$79.00 ➝ $85.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$72.00 ➝ $82.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$63.00 ➝ $73.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$78.00 ➝ $82.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $85.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$74.00 ➝ $90.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$80.00 ➝ $85.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$72.00 ➝ $78.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$14.81B1.38$5.14 per share7.81$16.69 per share2.40
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$19.37B3.45$20.03 per share11.56$88.92 per share2.60
Boston Scientific Co. stock logo
BSX
Boston Scientific
$14.24B7.54$2.91 per share25.11$13.33 per share5.49
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B13.59$1.87 per share66.63$5.35 per share23.24
3M stock logo
MMM
3M
$32.68B1.55$12.84 per share7.15$8.81 per share10.42

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
$2.66B$5.227.6912.542.2017.77%19.49%4.77%5/2/2024 (Confirmed)
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.48B$4.2254.8716.171.936.44%13.57%6.56%5/2/2024 (Confirmed)
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.59B$1.1961.4928.812.4812.06%16.63%9.24%7/25/2024 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.3194.9255.762.3714.95%28.31%9.74%7/25/2024 (Estimated)
3M stock logo
MMM
3M
-$7.00B-$12.63N/A10.921.82-21.40%62.45%10.45%4/30/2024 (Confirmed)

Latest BSX, BDX, BAX, DXCM, and MMM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Baxter International Inc. stock logo
BAX
Baxter International
$0.61N/A-$0.61N/AN/AN/A  
5/2/2024N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.96N/A-$2.96N/AN/AN/A  
4/30/2024N/A
3M stock logo
MMM
3M
$2.08N/A-$2.08N/AN/AN/A  
4/25/2024Q1 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.27$0.32+$0.05$0.28$911.20 million$921.00 million  
2/8/2024Q4 2023
Baxter International Inc. stock logo
BAX
Baxter International
$0.86$0.88+$0.02$1.28$3.81 billion$3.89 billion    
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      
2/1/2024Q1 2024
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.39$2.68+$0.29$4.40$4.73 billion$4.71 billion      
1/31/2024Q4 23
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.51$0.55+$0.04$0.76$3.59 billion$3.73 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$1.162.89%+6.70%22.22%N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.801.64%+4.77%90.05%52 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
3M stock logo
MMM
3M
$6.046.58%+0.68%N/A 67 Years

Latest BSX, BDX, BAX, DXCM, and MMM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/12/2024
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.292.88%2/29/20243/1/20244/1/2024
2/6/2024
3M stock logo
MMM
3M
quarterly$1.516.44%2/15/20242/16/20243/12/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.31
1.48
1.04
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.56
1.08
0.64
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.44
1.32
0.82
DexCom, Inc. stock logo
DXCM
DexCom
1.18
2.84
2.48
3M stock logo
MMM
3M
2.69
1.07
0.76

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
3M stock logo
MMM
3M
65.25%

Insider Ownership

CompanyInsider Ownership
Baxter International Inc. stock logo
BAX
Baxter International
0.21%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.31%
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
3M stock logo
MMM
3M
0.34%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
60,000507.83 million506.76 millionOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
73,000288.90 million288.01 millionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
48,0001.47 billion1.46 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600396.03 million394.40 millionOptionable
3M stock logo
MMM
3M
85,000553.36 million551.48 millionOptionable

BSX, BDX, BAX, DXCM, and MMM Headlines

SourceHeadline
Roffman Miller Associates Inc. PA Lowers Stock Position in 3M (NYSE:MMM)Roffman Miller Associates Inc. PA Lowers Stock Position in 3M (NYSE:MMM)
marketbeat.com - April 26 at 2:52 PM
Market Underdogs: 3 Stocks Ready to Beat Earnings With Some Serious BiteMarket Underdogs: 3 Stocks Ready to Beat Earnings With Some Serious Bite
investorplace.com - April 26 at 1:46 PM
3M (NYSE:MMM)  Shares Down 1.1% 3M (NYSE:MMM) Shares Down 1.1%
marketbeat.com - April 25 at 7:07 PM
Heres How You Should Play 3M (MMM) Stock Ahead of Q1 EarningsHere's How You Should Play 3M (MMM) Stock Ahead of Q1 Earnings
zacks.com - April 25 at 2:05 PM
Sell Any Rally Now and Grab These Passive Income Dividend KingsSell Any Rally Now and Grab These Passive Income Dividend Kings
247wallst.com - April 25 at 9:40 AM
3M (NYSE:MMM) Lifted to Strong-Buy at StockNews.com3M (NYSE:MMM) Lifted to Strong-Buy at StockNews.com
americanbankingnews.com - April 25 at 2:20 AM
Wynn Capital LLC Buys Shares of 11,386 3M (NYSE:MMM)Wynn Capital LLC Buys Shares of 11,386 3M (NYSE:MMM)
marketbeat.com - April 24 at 6:37 PM
3M (NYSE:MMM) Stock Price Down 1%3M (NYSE:MMM) Stock Price Down 1%
marketbeat.com - April 24 at 5:17 PM
6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income
247wallst.com - April 24 at 7:30 AM
3M (MMM) Ascends But Remains Behind Market: Some Facts to Note3M (MMM) Ascends But Remains Behind Market: Some Facts to Note
zacks.com - April 23 at 6:51 PM
3M (NYSE:MMM) Trading 1.4% Higher 3M (NYSE:MMM) Trading 1.4% Higher
marketbeat.com - April 23 at 3:20 PM
3M (NYSE:MMM) Shares Sold by Illinois Municipal Retirement Fund3M (NYSE:MMM) Shares Sold by Illinois Municipal Retirement Fund
marketbeat.com - April 23 at 1:04 PM
Analysts Estimate 3M (MMM) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate 3M (MMM) to Report a Decline in Earnings: What to Look Out for
zacks.com - April 23 at 11:06 AM
3M (MMM) Set to Announce Earnings on Tuesday3M (MMM) Set to Announce Earnings on Tuesday
americanbankingnews.com - April 23 at 4:32 AM
3M (MMM) Set to Announce Quarterly Earnings on Tuesday3M (MMM) Set to Announce Quarterly Earnings on Tuesday
marketbeat.com - April 23 at 4:30 AM
Paramount Global CEO Bob Bakishs 2023 Pay Totals $31.3M, Down Slightly From Prior YearParamount Global CEO Bob Bakish's 2023 Pay Totals $31.3M, Down Slightly From Prior Year
deadline.com - April 22 at 6:20 PM
3M (NYSE:MMM)  Shares Down 0.1% 3M (NYSE:MMM) Shares Down 0.1%
marketbeat.com - April 22 at 2:33 PM
3M Co DRC (MMM)3M Co DRC (MMM)
uk.investing.com - April 21 at 9:15 PM
Commerzbank Aktiengesellschaft FI Sells 8,919 Shares of 3M (NYSE:MMM)Commerzbank Aktiengesellschaft FI Sells 8,919 Shares of 3M (NYSE:MMM)
marketbeat.com - April 21 at 5:22 PM
3M (NYSE:MMM) Trading 0.4% Higher 3M (NYSE:MMM) Trading 0.4% Higher
americanbankingnews.com - April 21 at 4:42 AM
Allspring Global Investments Holdings LLC Trims Stock Holdings in 3M (NYSE:MMM)Allspring Global Investments Holdings LLC Trims Stock Holdings in 3M (NYSE:MMM)
marketbeat.com - April 20 at 5:14 AM
HTLF Bank Invests $1.42 Million in 3M (NYSE:MMM)HTLF Bank Invests $1.42 Million in 3M (NYSE:MMM)
marketbeat.com - April 19 at 11:45 AM
3M Stock Has 20% Upside, According to 1 Wall Street Analyst3M Stock Has 20% Upside, According to 1 Wall Street Analyst
fool.com - April 19 at 11:18 AM
6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer
247wallst.com - April 19 at 9:41 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Baxter International logo

Baxter International

NYSE:BAX
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Becton, Dickinson and Company logo

Becton, Dickinson and Company

NYSE:BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Boston Scientific logo

Boston Scientific

NYSE:BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
3M logo

3M

NYSE:MMM
3M Company provides diversified technology services in the United States and internationally. The company's Safety and Industrial segment offers industrial abrasives and finishing for metalworking applications; autobody repair solutions; closure systems for personal hygiene products, masking, and packaging materials; electrical products and materials for construction and maintenance, power distribution, and electrical original equipment manufacturers; structural adhesives and tapes; respiratory, hearing, eye, and fall protection solutions; and natural and color-coated mineral granules for shingles. Its Transportation and Electronics segment provides ceramic solutions; attachment/bonding products, films, sound, and temperature management for transportation vehicles; premium large format graphic films for advertising and fleet signage; light management films and electronics assembly solutions; packaging and interconnection solutions; semiconductor production materials; data centers solutions; and reflective signage for highway, and vehicle safety. The company's Consumer segment provides consumer bandages, braces, supports, and consumer respirators; home cleaning products; retail abrasives, paint accessories, car care DIY products, picture hanging, and consumer air quality solutions; and stationery products. It offers its products through e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers. 3M Company was founded in 1902 and is headquartered in Saint Paul, Minnesota.